Corcept Therapeutics Incorporated (CORT)
| Market Cap | 4.79B |
| Revenue (ttm) | 741.17M +17.9% |
| Net Income | 104.66M -25.2% |
| EPS | 0.87 -30.7% |
| Shares Out | 105.19M |
| PE Ratio | 52.09 |
| Forward PE | 94.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 591,488 |
| Open | 45.53 |
| Previous Close | 45.64 |
| Day's Range | 43.52 - 46.00 |
| 52-Week Range | 32.99 - 117.33 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 114.20 (+150.99%) |
| Earnings Date | Feb 25, 2026 |
About CORT
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t... [Read more]
Financial Performance
In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CORT stock is "Buy." The 12-month stock price target is $114.2, which is an increase of 150.99% from the latest price.
News
Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps
Corcept Therapeutics Incorporated (NASDAQ: CORT) stock is trading higher on Thursday, with a session volume of 3.06 million.
Corcept's cancer drug meets main goal in late-stage trial
Corcept Therapeutics said on Thursday that its experimental cancer drug met the main goal in a late-stage study.
Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
LOS ANGELES, Jan. 15, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics ...
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT
LOS ANGELES--(BUSINESS WIRE)--Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT.
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman
Partner Reed Kathrein Urges Investors to Contact Firm SAN FRANCISCO, Jan. 14, 2026 /PRNewswire/ -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50...
CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses
Boston, Massachusetts--(Newsfile Corp. - January 13, 2026) - Block & Leviton is investigating Corcept Therapeutics Inc. (NASDAQ: CORT) for potential securities law violations. Investors who have lost ...
Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT)
New York, New York--(Newsfile Corp. - January 12, 2026) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeu...
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman
SAN FRANCISCO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced...
Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT)
NEW YORK--(BUSINESS WIRE)-- #investigation--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorpora...
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT)
New York, New York--(Newsfile Corp. - January 7, 2026) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeut...
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug
Corcept Therapeutics (CORT) leverages Korlym's commercial success in hypercortisolism, generating $559.3M in nine-month 2025 revenue and $19M Q3 net income. Despite positive Phase 3 data, the FDA unex...
Why Corcept Therapeutics stock crashed today and what comes next?
Corcept Therapeutics (NASDAQ: CORT) crashed about 50% on Dec. 31 after the FDA requested additional data to support the efficacy of relacorilant, its candidate treatment for Cushing's syndrome. The se...
Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug
The FDA cited insufficient evidence of effectiveness for relacorilant in patients with Cushing syndrome and hypertension, sending the stock sharply lower.
US FDA declines to approve Corcept's drug for rare hormonal disorder
The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' hormone-blocking drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?
Are There Red Flags in the Trial Results?
Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript
Corcept Therapeutics Incorporated ( CORT) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Sean M...
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 202...
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Transition To New Specialty Pharmacy Well Underway
Corcept Therapeutics (CORT) has added Curant Rare as a second specialty pharmacy to handle increased prescription demand for Korlym. Optime Care will discontinue servicing CORT prescriptions due to it...
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics
ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare has been selected by Corcept Therapeutics as a specialty pharmacy to provide personalized care, coordinated access to ther...